{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:19:51Z","timestamp":1794374391665,"version":"4.9.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"37","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL167858"],"award-info":[{"award-number":["R01HL167858"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23HL153775"],"award-info":[{"award-number":["K23HL153775"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1F32HL170592"],"award-info":[{"award-number":["1F32HL170592"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BridgeBio","id":[{"id":"https:\/\/ror.org\/0394gjn55","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005326","name":"Yale University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>The diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) requires advanced imaging, precluding large-scale preclinical testing. Artificial intelligence (AI)-enabled transthoracic echocardiography (TTE) and electrocardiography (ECG) may provide a scalable strategy for preclinical monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective analysis of individuals referred for nuclear cardiac amyloid testing at the Yale-New Haven Health System (YNHHS, internal cohort) and Houston Methodist Hospitals (HMH, external cohort). Deep learning models trained to discriminate ATTR-CM from age\/sex-matched controls on TTE videos (AI-Echo) and ECG images (AI-ECG) were deployed to generate study-level ATTR-CM probabilities (0%\u2013100%). Longitudinal trends in AI-derived probabilities were examined using age\/sex-adjusted linear mixed models, and their discrimination of future disease was evaluated across preclinical stages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 984 participants at YNHHS (median age 74 years, 44.3% female) and 806 at HMH (median age 69 years, 34.5% female), 112 (11.4%) and 174 (21.6%) tested positive for ATTR-CM, respectively. Across cohorts and modalities, AI-derived ATTR-CM probabilities from 7352 TTEs and 32 205 ECGs diverged as early as 3 years before diagnosis in cases vs controls (ptime(x)group interaction \u00a0\u2264 .004). Among those with both AI-Echo and AI-ECG probabilities available 1 to 3 years before nuclear testing [n = 433 (YNHHS) sand 174 (HMH)], a double-negative screen at a 0.05 threshold [164 (37.9%) and 66 (37.9%), vs all else] had 90.9% and 85.7% sensitivity (specificity of 40.3% and 41.2%), whereas a double-positive screen [78 (18.0%) and 26 (14.9%), vs all else] had 85.5% and 88.9% specificity (sensitivity of 60.6% and 42.9%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Artificial intelligence\u2013enabled echocardiography and electrocardiography may enable scalable risk stratification of ATTR-CM during its preclinical course.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaf450","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T10:05:42Z","timestamp":1752746742000},"page":"3651-3662","source":"Crossref","is-referenced-by-count":46,"title":["Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy"],"prefix":"10.1093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4362-0720","authenticated-orcid":false,"given":"Evangelos K","family":"Oikonomou","sequence":"first","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine , New Haven, CT ,","place":["USA"]},{"name":"Cardiovascular Data Science (CarDS) Lab, Yale School of Medicine , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8524-1203","authenticated-orcid":false,"given":"Veer","family":"Sangha","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine , New Haven, CT ,","place":["USA"]},{"name":"Cardiovascular Data Science (CarDS) Lab, Yale School of Medicine , New Haven, CT ,","place":["USA"]},{"name":"Department of Engineering Science, University of Oxford , Oxford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3034-0641","authenticated-orcid":false,"given":"Sumukh Vasisht","family":"Shankar","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine , New Haven, CT ,","place":["USA"]},{"name":"Cardiovascular Data Science (CarDS) Lab, Yale School of Medicine , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Coppi","sequence":"additional","affiliation":[{"name":"Cardiovascular Data Science (CarDS) Lab, Yale School of Medicine , New Haven, CT ,","place":["USA"]},{"name":"Center for Outcomes Research and Evaluation, Yale-New Haven Hospital , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2046-127X","authenticated-orcid":false,"given":"Harlan M","family":"Krumholz","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine , New Haven, CT ,","place":["USA"]},{"name":"Center for Outcomes Research and Evaluation, Yale-New Haven Hospital , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khurram","family":"Nasir","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center , Houston, TX ,","place":["USA"]},{"name":"Houston Methodist-Rice Digital Health Institute , Houston, TX ,","place":["USA"]},{"name":"Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital , Houston, TX ,","place":["USA"]},{"name":"Center for Cardiovascular Computational and Precision Health, Houston Methodist DeBakey Heart & Vascular Center , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J","family":"Miller","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesia","family":"Gallegos Kattan","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouaz H","family":"Al-Mallah","sequence":"additional","affiliation":[{"name":"Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1122-7695","authenticated-orcid":false,"given":"Sadeer","family":"Al-Kindi","sequence":"additional","affiliation":[{"name":"Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital , Houston, TX ,","place":["USA"]},{"name":"Center for Cardiovascular Computational and Precision Health, Houston Methodist DeBakey Heart & Vascular Center , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9467-6199","authenticated-orcid":false,"given":"Rohan","family":"Khera","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine , New Haven, CT ,","place":["USA"]},{"name":"Cardiovascular Data Science (CarDS) Lab, Yale School of Medicine , New Haven, CT ,","place":["USA"]},{"name":"Center for Outcomes Research and Evaluation, Yale-New Haven Hospital , New Haven, CT ,","place":["USA"]},{"name":"Section of Biomedical Informatics and Data Science, Yale School of Medicine , New Haven, CT ,","place":["USA"]},{"name":"Section of Health Informatics, Department of Biostatistics, Yale School of Public Health , 195 Church St, 6th Floor, New Haven, CT 06510 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"2025100219515971500_ehaf450-B1","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology solution set oversight committee","volume":"81","author":"Writing Committee","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025100219515971500_ehaf450-B2","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann Med"},{"key":"2025100219515971500_ehaf450-B3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jacc.2017.11.037","article-title":"Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement","volume":"71","author":"Scully","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2025100219515971500_ehaf450-B4","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"key":"2025100219515971500_ehaf450-B5","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"6","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2025100219515971500_ehaf450-B6","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"2025100219515971500_ehaf450-B7","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2025100219515971500_ehaf450-B8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"2025100219515971500_ehaf450-B9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"2025100219515971500_ehaf450-B10","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"2025100219515971500_ehaf450-B11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"2025100219515971500_ehaf450-B12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N Engl J Med"},{"key":"2025100219515971500_ehaf450-B13","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"2025100219515971500_ehaf450-B14","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1016\/S2589-7500(23)00265-0","article-title":"Diagnosis and prognosis of abnormal cardiac scintigraphy uptake suggestive of cardiac amyloidosis using artificial intelligence: a retrospective, international, multicentre, cross-tracer development and validation study","volume":"6","author":"Spielvogel","year":"2024","journal-title":"Lancet Digit Health"},{"key":"2025100219515971500_ehaf450-B15","doi-asserted-by":"publisher","author":"Sangha","DOI":"10.1101\/2024.09.30.24314651"},{"key":"2025100219515971500_ehaf450-B16","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/S2589-7500(24)00249-8","article-title":"Artificial intelligence-guided detection of under-recognised cardiomyopathies on point-of-care cardiac ultrasonography: a multicentre study","volume":"7","author":"Oikonomou","year":"2025","journal-title":"Lancet Digit Health"},{"key":"2025100219515971500_ehaf450-B17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s43856-024-00538-3","article-title":"Efficient deep learning-based automated diagnosis from echocardiography with contrastive self-supervised learning","volume":"4","author":"Holste","year":"2024","journal-title":"Commun Med (Lond)"},{"key":"2025100219515971500_ehaf450-B18","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1093\/eurheartj\/ehad456","article-title":"Severe aortic stenosis detection by deep learning applied to echocardiography","volume":"44","author":"Holste","year":"2023","journal-title":"Eur Heart J"},{"key":"2025100219515971500_ehaf450-B19","doi-asserted-by":"publisher","first-page":"e000029","DOI":"10.1161\/HCI.0000000000000029","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"2025100219515971500_ehaf450-B20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijcard.2019.12.063","article-title":"Diagnostic delay in wild type transthyretin cardiac amyloidosis\u2014a clinical challenge","volume":"304","author":"Ladefoged","year":"2020","journal-title":"Int J Cardiol"},{"key":"2025100219515971500_ehaf450-B21","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jamacardio.2024.0595","article-title":"A multimodal video-based AI biomarker for aortic stenosis development and progression","volume":"9","author":"Oikonomou","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2025100219515971500_ehaf450-B22","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1161\/CIRCULATIONAHA.122.062646","article-title":"Detection of left ventricular systolic dysfunction from electrocardiographic images","volume":"148","author":"Sangha","year":"2023","journal-title":"Circulation"},{"key":"2025100219515971500_ehaf450-B23","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/jamia\/ocae002","article-title":"Biometric contrastive learning for data-efficient deep learning from electrocardiographic images","volume":"31","author":"Sangha","year":"2024","journal-title":"J Am Med Inform Assoc"},{"key":"2025100219515971500_ehaf450-B24","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/s41467-022-29153-3","article-title":"Automated multilabel diagnosis on electrocardiographic images and signals","volume":"13","author":"Sangha","year":"2022","journal-title":"Nat Commun"},{"key":"2025100219515971500_ehaf450-B25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/13506129.2023.2229484","article-title":"Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay","volume":"30","author":"Coelho","year":"2023","journal-title":"Amyloid"},{"key":"2025100219515971500_ehaf450-B26","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.jacc.2023.12.036","article-title":"Stratifying disease progression in patients with cardiac ATTR amyloidosis","volume":"83","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025100219515971500_ehaf450-B27","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1093\/eurheartj\/ehad139","article-title":"Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis","volume":"44","author":"Rauf","year":"2023","journal-title":"Eur Heart J"},{"key":"2025100219515971500_ehaf450-B28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"99mTc-Pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and Senile cardiac amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"2025100219515971500_ehaf450-B29","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1001\/jamacardio.2021.6059","article-title":"High-throughput precision phenotyping of left ventricular hypertrophy with cardiovascular deep learning","volume":"7","author":"Duffy","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2025100219515971500_ehaf450-B30","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1038\/s41467-021-22877-8","article-title":"Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms","volume":"12","author":"Goto","year":"2021","journal-title":"Nat Commun"},{"key":"2025100219515971500_ehaf450-B31","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1016\/j.mayocp.2021.04.023","article-title":"Artificial intelligence-enhanced electrocardiogram for the early detection of cardiac amyloidosis","volume":"96","author":"Grogan","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"2025100219515971500_ehaf450-B32","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2025100219515971500_ehaf450-B33","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2019.17935","article-title":"Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or hispanic\/latino ancestry","volume":"322","author":"Damrauer","year":"2019","journal-title":"JAMA"},{"key":"2025100219515971500_ehaf450-B34","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1001\/jamacardio.2023.1525","article-title":"Age dependency of cardiovascular outcomes with the amyloidogenic pV142I transthyretin variant among black individuals in the US","volume":"8","author":"Selvaraj","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2025100219515971500_ehaf450-B35","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jama.2024.4467","article-title":"Cardiovascular burden of the V142I transthyretin variant","volume":"331","author":"Selvaraj","year":"2024","journal-title":"JAMA"},{"key":"2025100219515971500_ehaf450-B36","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"2025100219515971500_ehaf450-B37","doi-asserted-by":"publisher","first-page":"101948","DOI":"10.1016\/j.nuclcard.2024.101948","article-title":"Rationale & design of ACT-EARLY, the acoramidis transthyretin amyloidosis prevention trial: early detection using cardiac radionuclide imaging","volume":"38","author":"Soman","year":"2024","journal-title":"J Nucl Cardiol"},{"key":"2025100219515971500_ehaf450-B38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s12170-021-00670-y","article-title":"Racial and ethnic disparities in transthyretin cardiac amyloidosis","volume":"15","author":"Spencer-Bonilla","year":"2021","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"2025100219515971500_ehaf450-B39","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1093\/eurheartj\/ehae415","article-title":"Artificial intelligence-enhanced patient evaluation: bridging art and science","volume":"45","author":"Oikonomou","year":"2024","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/37\/3651\/63794924\/ehaf450.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/37\/3651\/63794924\/ehaf450.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:52:05Z","timestamp":1759449125000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/46\/37\/3651\/8206181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":39,"journal-issue":{"issue":"37","published-online":{"date-parts":[[2025,7,18]]},"published-print":{"date-parts":[[2025,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf450","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,1]]},"published":{"date-parts":[[2025,7,18]]}}}